Opendata, web and dolomites

Lottare GBM SIGNED

LOcalized Targeted Therapy to Avoid REcurrent GlioBlastoma Multiforme

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lottare GBM project word cloud

Explore the words cloud of the Lottare GBM project. It provides you a very rough idea of what is the project "Lottare GBM" about.

targtex    neuro    safer    team    primary    gbm    regulatory    cells    months    conundrum    slow    glioblastoma    purpose    rate    drug    brings    tissue    disease    removing    tumor    trial    small    pharmacology    investors    adoption    unaffected    newly    active    hydrogel    safety    terrible    ip    feasibility    lack    toxicology       neurosurgeons    aggressiveness    scientists    life    financial    cycles    patients    contributions    translates    solution    prognosis    resection    competition    startup    survival    ema    18    strategy    diagnosed    weeks    consideration    surgery    innovative    brain    context    chemotherapy    combined    deal    clinical    personalized    founded    oncologists    added    aggressive    doctors    treatment    12    lower    experiments    multiforme    pharma    concerted    molecule    lethal    expectancy    treatments    medicine    commercial    portuguese    willingness    removed    formulation    selectively    recurrence    binds    patient    benefits    single    population    release    adjunct    protecting    kill    stakeholders    covers    framework    tackle   

Project "Lottare GBM" data sheet

The following table provides information about the project.

Coordinator
TARGTEX SA 

Organization address
address: AVENIDA TENENTE VALADIM, N 17, 2 F
city: Torres Vedras
postcode: 2560-275
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARGTEX SA PT (Torres Vedras) coordinator 50˙000.00

Map

 Project objective

TargTex is a newly founded Portuguese startup with a novel concept to tackle the most lethal type of brain tumor – Glioblastoma Multiforme (GBM). GBM is the most common and aggressive type of primary brain tumor, with a survival rate lower than 5% after 2 years. The aggressiveness of the disease combined with the lack of effective treatments translates into a terrible prognosis to GBM patients, with a life expectancy of no more than 12 to 18 months after being diagnosed. TargTex team has developed a concerted approach, taking into consideration the needs and contributions from key stakeholders: patients, doctors and scientists. This innovative treatment (for which we have IP protecting the application) is based on a hydrogel formulation to be used as adjunct to surgery, applied after tumor resection. With a slow release from the hydrogel – over several weeks – the molecule is able to selectively kill GBM tumor cells that were not fully removed during surgery, thus offering a safer solution to neurosurgeons, who often deal with the conundrum of removing unaffected brain tissue to avoid tumor recurrence. In addition, this approach brings added benefits to the patients since the single treatment does not require further chemotherapy cycles. Most importantly, the active drug is a small molecule that binds to a specific target in GBM cells, and therefore, covers the whole patient population since it is not a personalized medicine. Our goal for the Phase 1 is to assess the technical, commercial and financial feasibility of TargTex. For that purpose, we will a) assess the regulatory framework and IP strategy to develop an adjunct to surgery in the context of GBM; 2) design the Toxicology & Safety Pharmacology experiments needed for an EMA’s Clinical Trial application; 3) assess the willingness to adoption of our solution from neuro-oncologists and neurosurgeons and 4) evaluate competition and assess the interest of investors and pharma towards our unique product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOTTARE GBM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOTTARE GBM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More